Proton pump inhibitors (PPIs) prescribed alongside CDK4/6 inhibitors for hormone receptor-positive, HER2-negative breast cancer may correlate with reduced survival outcomes, according to a nationwide study published in The Oncologist on Friday.
Researchers found that patients taking both types of medication experienced shorter progression-free and overall survival rates compared to those not using acid-suppressive therapy.
- Out of 6,435 patients studied, 574 individuals—or 8.9%—maintained overlapping prescriptions for PPIs and CDK4/6 inhibitors.
- Adjusted data show a hazard ratio of 1.33 for progression-free survival and 1.54 for overall survival among PPI users.
- A retrospective study of patients receiving ribociclib or palbociclib found that PPI use was an independent predictor of reduced progression-free survival.
PPI exposure was defined as at least 30 days of overlapping prescriptions during the first 90 days of treatment.
While the findings indicate a statistical association between PPI use and poorer outcomes, the authors said that “residual confounding, including differences in the indications for PPI use, may contribute to these associations.” Because patients requiring PPIs may have underlying conditions that naturally impact prognosis, the study cannot confirm that discontinuing the acid suppressants would directly improve survival.
The unweighted estimates from the Korean study were in the same direction, with a real-world progression-free survival hazard ratio of 1.32 and an overall survival hazard ratio of 1.65.
Pharmacokinetic interactions offer one potential explanation for the trend. PPIs increase gastric pH, which can hinder the dissolution and absorption of certain CDK4/6 inhibitor formulations, such as palbociclib in capsule form, particularly if taken while fasting. “Taking the capsule with food, as prescribed, substantially attenuates this effect,” Kefah Mokbel, an honorary professor of medicine at Cardiff University, noted in commentary shared on LinkedIn.
Mokbel suggested that clinicians should review the necessity of PPI prescriptions when starting a patient on a CDK4/6 inhibitor. He proposed that for patients with ongoing acid-related needs, providers could consider switching to a tablet formulation—which may be less sensitive to pH changes—or opting for as-needed antacids in cases of mild reflux.
Researchers continue to study how concomitant therapy affects patients. A separate retrospective analysis of 92 patients observed a significant divergence in outcomes among a ribociclib-dominant cohort, where PPI use was identified as an independent predictor of reduced progression-free survival.
In this ribociclib-only cohort (n = 86), the association persisted with an adjusted hazard ratio of 6.36. The researchers behind that analysis emphasized that their results should be interpreted as associational and called for further prospective, agent-specific studies to clarify the clinical significance of these drug-drug interactions.
The nationwide Korean study led by Kyung-Hun Lee and colleagues utilized data from the National Health Insurance Service to track over 7,200 patients initiating CDK4/6 inhibitor therapy.
While the study highlighted significant hazard ratios for both progression-free and overall survival, authors emphasized that these findings should be interpreted with caution. Because the study could not definitively rule out residual confounding related to the underlying reasons for PPI use, they said that the data do not confirm a causal link between discontinuing acid suppressants and improved patient prognosis.
Separate clinical investigations have sought to clarify how these drug interactions manifest in specific treatment groups.
Researchers involved in these analyses stressed the need for prospective, agent-specific studies to fully understand the clinical impact of these interactions.
Keep reading